Expect initial negative reaction to the deep EPS miss and revenue decline, but monitor for a potential recovery if the FDA resubmission progresses as planned in Q2. The maintained guidance suggests management sees the production issues as temporary, providing a possible floor.
Price Chart
Executive Summary
Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due to a production slowdown that impacted revenues and EBITDA. Management maintained 2026 revenue guidance of $650-700M and outlined progress on FDA resubmission and pipeline, but the weak quarterly results will likely pressure the stock near term.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $105.9M vs $132.8M YoY (down 20.3%)
- GAAP EPS -$0.37 vs consensus $0.06 (miss of -716.7%)
- Adjusted EBITDA $24.4M with gross margin of 57%
- Management maintained 2026 revenue guidance of $650-700M and adjusted EBITDA guidance of $180-220M
- Production slowdown related to facility improvements impacted quarterly results
- FDA BLA resubmission planned for Q2 2026; pipeline advances including AVT16/AVT80 submissions and AVT29 pivotal study
- Entered into strategic manufacturing agreement with FUJIFILM Biotechnologies
Financial Impact
Revenue declined ~$27M YoY; EPS missed consensus by $0.43 per share
Risk Factors
- Further delays in FDA resubmission or rejection of BLAs
- Prolonged production disruptions impacting future revenue
- Competitive pressure in biosimilar markets
- Execution risk on pipeline milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 21d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers